<DOC>
	<DOCNO>NCT02650596</DOCNO>
	<brief_summary>The investigator plan evaluate effect liraglutide leave ventricular function chronic heart failure patient type 2 diabetes .</brief_summary>
	<brief_title>Effects GLP-1 Chronic Heart Failure</brief_title>
	<detailed_description>Heart failure ( HF ) major cause morbidity mortality world wide . Glucagon-like peptide-1 ( GLP-1 ) incretin hormone regulate plasma glucose , direct effect cardiovascular system . In previous study , GLP-1 analogue liraglutide could improve leave ventricular function patient acute myocardial infarction . However , effect GLP-1 chronic heart failure patient type 2 diabetes remain unclear . The aim study evaluate effect liraglutide leave ventricular function chronic heart failure patient type 2 diabetes .</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Glucagon-Like Peptide 1</mesh_term>
	<mesh_term>Liraglutide</mesh_term>
	<criteria>Chronic heart failure patient type 2 diabetes ( NYHAclass I , II III ) eligible study CHF ( NYHA class IV ) Type 1 diabetes Hospitalisation due incompensated heart disease within 30 day prior randomisation Myocardial infarction within past 3 month screen Coronary revascularisation within past 3 month screen Atrial fibrillation ventricular frequency &gt; 100/min rest ECG suggestive malignant ventricular arrhythmia Prolonged QTinterval ( &gt; 500 m ) Valvular heart disease Current myocardial pericardial infection Obstructive hypertrophic cardiomyopathy Cancer unless complete remission â‰¥5 year Acute pancreatitis Compromised kidney function ( eGFR &lt; 30 mL/min ) , dialysis kidney transplantation History thyroidea adenoma carcinoma</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>January 2016</verification_date>
</DOC>